NCT04715061

Brief Summary

Aerobic exercise is associated with many benefits in patients with cancer treatments. Among these, the reduction of cancer-related fatigue (CRF) is one of the best demonstrated. Besides, several animal models have shown a marked reduction in tumor growth with aerobic exercise, sometimes by more than 60%. As the level of physical activity is convincingly associated with a reduction in the risk of cancer or recurrences, this suggests that aerobic exercise may represent a central therapeutic approach during treatment, both against CRF and for its potential anti-tumor effect. Both benefits have been suggested to be based on the immunostimulatory and anti-inflammatory effects of exercise. Indeed, systemic inflammatory activity seems to play a central role in the etiology of CRF during cancer treatments, among other things by stimulating the neuro-inflammatory activity of the central nervous system. Also, regarding the anti-tumor effect of exercise, animal models show that this benefit is partly explained by an increase in the activity of immune cells called natural killers (Natural Killer; NK) in tumor tissue and a reduction in the activity of regulatory T cells, the latter having an immunosuppressive effect. However, in humans, the results vary. While some improvement in NK cell activity has been reported in response to aerobic training in breast cancer survivors, others have seen no effect on the immune profile of patients and survivors. On the other hand, some authors report an improvement in the inflammatory profile with training, while others report little or no effect, as well as weak associations with the perception of fatigue. Although these results seem to discredit the hypothesis of immune and inflammatory regulation of exercise in humans, these studies have all looked at the effect of several weeks of training on the inflammatory and immune profile on an empty stomach and rest. However, several results from the field of exercise immunology convincingly show that the anti-inflammatory effect, as well as the immunostimulating effect of aerobic exercise (including the anti-tumor activity of NK cells) are mainly acute and transient, ie. in the hours following the end of the effort. Furthermore, certain results suggest that in the context of chemotherapy treatments, cyclical treatment by nature, the peaks of fatigue are also acute (i.e. in the days following the treatment) and parallel to peaks of inflammatory activity. Considering these results, it is therefore plausible to assume that the effect of aerobic exercise on suppressing tumor growth and reducing CRF results rather than the repetition of this acute response at each exercise session. In this case, the prescription of aerobic exercise preceding a session of chemotherapy could potentially represent an interesting therapeutic modality, allowing both the reduction of the CRF associated with this treatment, as well as a better response to the treatment. Besides, as this acute response seems to be highly dependent on the intensity of the effort, high-intensity interval training (HIIT) could be a particularly interesting approach in this context, because it does not require that the high intensity or long-lasting exercise. However, considering the immunosuppressive and pro-inflammatory effects of chemotherapy, the extent of the acute response to exercise may not allow this type of therapeutic use to be considered in this population. To date, no study has attempted to characterize the acute immune and inflammatory response following aerobic exercise in patients currently undergoing chemotherapy treatments.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 4, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 11, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 20, 2021

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 29, 2022

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 4, 2022

Completed
Last Updated

November 7, 2022

Status Verified

November 1, 2022

Enrollment Period

1.9 years

First QC Date

December 11, 2020

Last Update Submit

November 4, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in the concentration of different peripheral blood mononuclear cells (Natural Killer Cells, T cells and monocytes)

    Flow cytometry

    Before the start of the condition (t = 0 minute), at the end of the condition (t = 50 minutes), 1 hour post-condition (t = 110 minutes)

Secondary Outcomes (6)

  • Change in the concentration of inflammatory mediators in peripheral blood (chemokines, pro- and anti-inflammatory cytokines)

    Before the start of the condition (t = 0 minute), At the end of the condition (t = 50 minutes), 1 hour post-condition (t = 110 minutes), 2 hour post-condition (t = 170 minutes)

  • Change of hormonal profile (cortisol, corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), adrenaline and noradrenaline)

    Before the start of the condition (t = 0 minute), At the end of the condition (t = 50 minutes), 1 hour post-condition (t = 110 minutes), 2 hour post-condition (t = 170 minutes)

  • Change of Indoleamine-2,3-Dioxygenase activation

    Before the start of the condition (t = 0 minute), At the end of the condition (t = 50 minutes), 1 hour post-condition (t = 110 minutes), 2 hour post-condition (t = 170 minutes)

  • Cancer-Related Fatigue

    During 5 days after the day of the condition, 3 times per day

  • Cerebral integrity - Cerebral blood flow

    At the end of the condition (t = 50 minutes) within a 30-minute time window

  • +1 more secondary outcomes

Study Arms (3)

Cancer patients with MRI

EXPERIMENTAL

9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition (with MRI), then randomly MICE condition and HIIT condition (with MRI).

Other: Resting state (Control)Other: Moderate Intensity Continuous Exercise (MICE)Other: High Intensity Interval Exercise (HIIE)

Cancer patients without MRI

EXPERIMENTAL

9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition, then randomly MICE condition and HIIT condition, all without MRI.

Other: Resting state (Control)Other: Moderate Intensity Continuous Exercise (MICE)Other: High Intensity Interval Exercise (HIIE)

Healthy patients

ACTIVE COMPARATOR

9 healthy patients will be recruited and received 2 experimental conditions : first the rest condition (with a MRI), then HIIT condition (with MRI).

Other: Resting state (Control)Other: High Intensity Interval Exercise (HIIE)

Interventions

Participants were asking to sit on a sofa for 50 minutes.

Cancer patients with MRICancer patients without MRIHealthy patients

MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)

Cancer patients with MRICancer patients without MRI

HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).

Cancer patients with MRICancer patients without MRIHealthy patients

Eligibility Criteria

Age50 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of metastatic colorectal cancer
  • At the beginning of their chemotherapy treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status between grades 0 to 1
  • Physically capable to realise HIIT and continous moderate aerobic exercise on ergocycle

You may not qualify if:

  • Orthopedic, cardiac or metabolic limitations preventing aerobic effort
  • Betablockers
  • Surgery planned for the next two months following recruitment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Research Centre on Aging

Sherbrooke, Quebec, J1H 4C4, Canada

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

High-Intensity Interval Training

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

Physical Conditioning, HumanExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Model Details: Each participant performed 3 experimental conditions (rest, moderate continuous training and interval training).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 11, 2020

First Posted

January 20, 2021

Study Start

November 4, 2020

Primary Completion

September 29, 2022

Study Completion

October 4, 2022

Last Updated

November 7, 2022

Record last verified: 2022-11

Locations